BioSpace News Archive

Business

Mission Bio Announces New CEO to Manage a “Perfect Storm” for Accelerated Growth

She succeeds Mission Bio’s current chief executive officer Charlie Silver, who will shift into an advisory role with the company he co-founded.

April 8, 2021
·
5 min read
·
Gail Dutton
BioCapital

Research Roundup: A New Spin on Jurassic Park and More

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

April 8, 2021
·
5 min read
·
Mark Terry
Drug Development

Molecules from Probiotic-Rich Foods May Combat “Cytokine Storm” in COVID-19

A recent study from Ben-Gurion University of the Negev (BGU) found that isolated molecules from probiotic-rich dairy products could have potential as novel drug candidates for fighting against pathogenic bacteria and treating inflammatory diseases.

April 8, 2021
·
3 min read
·
Brandon May
Deals

Reneo Pharmaceuticals and VectivBio Prepare to Begin Trading on the Nasdaq

The wave of biopharma companies going public continues with two more companies setting sights on publicly trading on a stock exchange. Reneo Pharmaceuticals and VectivBio will both begin trading on the Nasdaq this week.

April 8, 2021
·
2 min read
·
Alex Keown
FDA

FDA May be Getting Tougher, but Gives Trodelvy Nod for Triple-Negative Breast Cancer

The agency granted full approval to Gilead Sciences’ Trodelvy (Sacituzumab govitecan-hziy) for adults with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who have received two or more previous system therapies, at least one for metastatic disease.

April 8, 2021
·
3 min read
·
Mark Terry
Policy

The Ebola Vaccine: A Cautionary Tale

The story of how the Ervebo came to be is not just an account of a broken contract, but also a cautionary tale.

April 8, 2021
·
5 min read
·
Heather McKenzie
Business

Ventus Scoops Up $100 Million to Take NLRP3 Inhibitor to the Clinic

Eleven months after launching with $60 million in hand, Ventus Therapeutics has raised another $100 million to drive its pipeline toward the clinic.

April 8, 2021
·
2 min read
·
Kate Goodwin
BioSpace Movers & Shakers, April 9

Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

April 8, 2021
·
8 min read
·
Alex Keown
eDNA from Air Yields Data for Social Distancing, Disease Transmission and More

The technology also has intriguing potential in DNA forensics, even without the presence of other physical samples.

April 8, 2021
·
4 min read
·
Gail Dutton
Drug Development

Lilly and Incyte’s Olumiant Shows Mixed Results Against COVID-19

Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.

April 8, 2021
·
4 min read
·
Mark Terry